Intellia TherapeuticsNTLA +1.59%71 PS Ratio is 30.41 as of Jul. 07, 2026, which is 9% below its 10-year median of 33.28. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.53 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Intellia Therapeutics ranks worse than 72.66% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Intellia Therapeutics's share price is $17.85.
Intellia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.59. Hence, Intellia Therapeutics's PS Ratio for today is 30.41.
The historical rank and industry rank for Intellia Therapeutics's PS Ratio or its related term are showing as below:
NTLA'
s PS Ratio Range Over the Past 10 Years
Min: 12.52 Med: 33.28 Max: 340.4
Current: 30.41
During the past 12 years, Intellia Therapeutics's highest PS Ratio was 340.40. The lowest was 12.52. And the median was 33.28.
NTLA's PS Ratio is ranked worse than 72.66% of 929
companies
in the Biotechnology industry
Industry Median: 9.64
vs NTLA: 30.41
Intellia Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Intellia Therapeutics was 30.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -2.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 12 years, Intellia Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 27.40% per year. The lowest was -26.60% per year. And the median was 2.20% per year.
Back to Basics: PS Ratio
Intellia Therapeutics (NAS:NTLA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intellia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Intellia Therapeutics's Share Price of today is $17.85. Intellia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Intellia Therapeutics (NTLA) has a PS Ratio of 30.41 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Intellia Therapeutics and its competitors. This is near median its historical median of 33.28. Over the past decade, Intellia Therapeutics' PS Ratio has ranged from 12.52 to 340.40. According to the industry distribution chart, Intellia Therapeutics ranks #675 out of 929 companies in the Biotechnology industry, placing it in the top 72.7%.
Is Intellia Therapeutics' PS Ratio too high?
Intellia Therapeutics' current PS Ratio of 30.41 is near median its 10-year median of 33.28. Over the past 10 years, this metric has ranged from a low of 12.52 to a high of 340.40. The Biotechnology industry median PS Ratio is 9.64. Intellia Therapeutics' value of 30.41 is 215.5% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #675 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' PS Ratio compare to MLYS and VCEL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #675 out of 929 companies for PS Ratio. This places Intellia Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.64. Intellia Therapeutics' value of 30.41 is 215.5% above this benchmark. Historically, Intellia Therapeutics' own PS Ratio has ranged from 12.52 to 340.40 over the past decade. While the company's 10-year median is 33.28 vs. the industry median of 9.64, Intellia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current PS Ratio of 30.41 is 215.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Intellia Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current PS Ratio is 30.41, which is near median its own 10-year median of 33.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.53, compared to a current price of $17.85 — trading 13.1% below its estimated fair value. The current PS Ratio is 30.41, which is near median its 10-year median of 33.28 and 215.5% above the Biotechnology industry median of 9.64. Intellia Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current PS Ratio is 30.41 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $17.85 is trading 13.1% below its estimated GF Value™ of $20.53.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
PS Ratio: 30.41 (near median its 10-year median of 33.28)
GF Value™: $20.53 vs. price of $17.85 (13.1% below fair value)
Industry Position: 215.5% above the Biotechnology median (#675 of 929)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
71GF Score
Get the complete analysis for NTLA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
